ESMO 2022 | METEORA-II: metronomic VEX versus paclitaxel in ER+/HER2- metastatic breast cancer

Elisabetta Munzone, MD, Istituto Europeo di Oncologia, Milan, Italy, discusses the trial design of the Phase II randomized, multi-center METEORA-II trial (NCT02954055), which compared metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) to weekly paclitaxel in patients with ER+/HER2- metastatic breast cancer. 140 patients, who were pretreated with either chemotherapy or endocrine therapy, were randomized to receive either weekly paclitaxel or metronomic VEX therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.